Venus Remedies Gets GMP Approval for Pre-Filled Syringe Facility
By Rediff Money Desk, Chandigarh Nov 05, 2024 14:36
Venus Remedies receives GMP approval from Malaysia's NPRA for its robotic pre-filled syringe facility, marking a significant milestone for the company's commitment to quality and technological innovation.
Chandigarh, Nov 5 (PTI) Pharma major Venus Remedies on Tuesday said it has received good manufacturing practices (GMP) approval from the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia for its robotic pre-filled syringe facility at Baddi unit.
This marks the first Pharmaceutical Inspection Co-operation Scheme (PIC/S) accreditation for Venus Remedies' pre-filled syringe (PFS) facility, the company said in a statement.
"Securing the PIC/S GMP accreditation from Malaysia's NPRA is a significant milestone and a testament to our commitment to quality and technological innovation in pharmaceutical manufacturing," Saransh Chaudhary, President, Global Critical Care, Venus Remedies and CEO, Venus Medicine Research Centre, said.
Chaudhary further noted that "the major technological upgrades and investments we've made in our PFS facility over recent years have culminated in this recognition, reinforcing our team's dedication and excellence."
The approval process for the facility, completed within six months of a rigorous audit in April 2024, underscores the high compliance standards and world-class quality control measures at Venus Remedies' Baddi facility.
Aditi Chaudhary, president of International Business at Venus Remedies, said, "the PIC/S GMP accreditation is a testament to the dedication and expertise of our teams across the globe. With this achievement, we are well-positioned to extend our international footprint and bring high-quality, life-saving medicines to more markets, thus ensuring better access to healthcare for all.
This marks the first Pharmaceutical Inspection Co-operation Scheme (PIC/S) accreditation for Venus Remedies' pre-filled syringe (PFS) facility, the company said in a statement.
"Securing the PIC/S GMP accreditation from Malaysia's NPRA is a significant milestone and a testament to our commitment to quality and technological innovation in pharmaceutical manufacturing," Saransh Chaudhary, President, Global Critical Care, Venus Remedies and CEO, Venus Medicine Research Centre, said.
Chaudhary further noted that "the major technological upgrades and investments we've made in our PFS facility over recent years have culminated in this recognition, reinforcing our team's dedication and excellence."
The approval process for the facility, completed within six months of a rigorous audit in April 2024, underscores the high compliance standards and world-class quality control measures at Venus Remedies' Baddi facility.
Aditi Chaudhary, president of International Business at Venus Remedies, said, "the PIC/S GMP accreditation is a testament to the dedication and expertise of our teams across the globe. With this achievement, we are well-positioned to extend our international footprint and bring high-quality, life-saving medicines to more markets, thus ensuring better access to healthcare for all.
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 8.41 (+ 2.44)
- 60373413
- Evexia Lifecare
- 3.94 (+ 4.79)
- 20851315
- Standard Capital
- 0.99 ( 0.00)
- 17601948
- Filatex Fashions
- 1.00 (+ 3.09)
- 16435485
- Sunshine Capital
- 2.21 (+ 4.74)
- 16004940
MORE NEWS
Akash Systems Signs USD 27 Million Server...
Akash Systems, a diamond semiconductor maker, has signed a USD 27 million contract with...
Krafton Enters India Casual Gaming with...
Krafton, known for BGMI, launches CookieRun in India, targeting casual gamers. The...
Bihar Seeks Investor Suggestions for Friendly...
Bihar's Industries Minister Nitish Mishra seeks input from investors to create more...